{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:11:11Z","timestamp":1789157471941,"version":"build-2803163510"},"reference-count":40,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:p>Aim: In this study, a series of novel aminocoumarin derivatives incorporating an amino-thiazole moiety were designed to evaluate their inhibitory activity against the carbonic anhydrase IX enzyme (PDB ID: 6fe0) and to explore their potential anti-neoplastic properties through molecular docking analysis.\nMaterials and Methods: Molecular docking was performed using the Molecular Operating Environment (MOE) software, version 2015.10. The Standard Score (S-score) and Root Mean Square Deviation (RMSD) parameters were used to evaluate the binding affinities of the ligands toward the target enzyme.\nResults: The four synthesized ligands (IIIa, IIIb, IIIc, and IIId) demonstrated stronger binding affinities to carbonic anhydrase IX compared with the reference ligand, acetazolamide. Among them, compound IIId showed the most favorable binding profile, having an S-score of -10.6.\nConclusions: These findings suggest that the produced 6-aminocoumarin derivatives, specifically compound IIId, could serve as promising, effective inhibitors of carbonic anhydrase with potential anti-cancer activity targeting the carbonic anhydrase IX enzyme.<\/jats:p>","DOI":"10.36740\/merkur202604107","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:47:48Z","timestamp":1789156068000},"page":"427","source":"Crossref","is-referenced-by-count":0,"title":["In silico study of thiazole-based amino coumarin derivatives with promising carbonic anhydrase inhibitory activity"],"prefix":"10.36740","volume":"54","author":[{"given":"Alaa H.","family":"Fadel","sequence":"first","affiliation":[{"name":"DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COLLEGE OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor H.","family":"Naser","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COLLEGE OF PHARMACY, AL-ZAHRAA UNIVERSITY FOR WOMEN, KARBALA, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022 Mar 18; 10(4):1367-1401. doi: 10.1016\/j.gendis.2022.02.007.","DOI":"10.1016\/j.gendis.2022.02.007"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: Cancer\u2010associated fibroblasts and their markers. Int J Cancer. 2020;146(4):895-905. doi: 10.1002\/ijc.32193.","DOI":"10.1002\/ijc.32193"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020 Mar 12; 5(1): 28. doi: 10.1038\/s41392-020-0134-x.","DOI":"10.1038\/s41392-020-0134-x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008 Sep;25(9):2097-116. doi: 10.1007\/s11095-008-9661-9.","DOI":"10.1007\/s11095-008-9661-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Baskar R, Itahana K. Radiation therapy and cancer control in developing countries: Can we save more lives? Int J Med Sci. 2017 Jan 1;14(1):13-17. doi:10.7150\/ijms.17288.","DOI":"10.7150\/ijms.17288"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019; 2(2): 141-160. doi: 10.20517\/cdr.2019.10.","DOI":"10.20517\/cdr.2019.10"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Tu\u011frak M, Gul MI, Sakagami H, Kaya R, Gulcin I, et al. Synthesis and biological evaluation of new pyrazolebenzene-sulphonamides as potentialanticancer agents and hCA I and II inhibitors. Turk J Chem. 2021 Jun 30; 45(3): 528-539. doi: 10.3906\/kim-2009-37.","DOI":"10.3906\/kim-2009-37"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Kalinin S, Malkova A, Sharonova T, Sharoyko V, Bunev A, Supuran CT, Krasavin M, et al. Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors. Int J Mol Sci. 2021;22(24):13405. doi: 10.3390\/ijms222413405.","DOI":"10.3390\/ijms222413405"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Abbas ZK, Naser NH, Atiya RN. In SilIco study of novel sulfonamide derivatives bearing A 1, 2, 4-Triazole moiety act as carbonic anhydrase inhibitors with promising anti-cancer activity. Pol Merk Lek. 2023;51(5):527-532. doi: 10.36740\/Merkur202305112.","DOI":"10.36740\/Merkur202305112"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Supuran, CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008 Feb;7(2):168-81. doi: 10.1038\/nrd2467.","DOI":"10.1038\/nrd2467"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018 Mar 21;8(2):25. doi: 10.3390\/metabo8020025.","DOI":"10.3390\/metabo8020025"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Akocak S, Supuran CT. Activation of \u03b1-, \u03b2-, \u03b3-\u03b4-, \u03b6-and \u03b7-class of carbonic anhydrases with amines and amino acids: a review. J Enzyme Inhib Med Chem. 2019 Sep 17;34(1):1652-1659. doi: 10.1080\/14756366.2019.1664501.","DOI":"10.1080\/14756366.2019.1664501"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. De Simone G, Supuran CT. (In) organic anions as carbonic anhydrase inhibitors. J Inorg Biochem. 2012 Jun:111:117-29. doi: 10.1016\/j.jinorgbio.2011.11.017.","DOI":"10.1016\/j.jinorgbio.2011.11.017"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Lomelino CL, Andring JT, McKenna R. Crystallography and its impact on carbonic anhydrase research. Int J Med Chem. 2018 Sep 13;2018:9419521. doi: 10.1155\/2018\/9419521.","DOI":"10.1155\/2018\/9419521"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem. 2007 Jul 1;15(13):4336-50. doi: 10.1016\/j.bmc.2007.04.020.","DOI":"10.1016\/j.bmc.2007.04.020"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Zhang Z-P, Yin Z-F, Li J-Y, Wang Z-P, Wu Q-J, et al., Synthesis, molecular docking analysis, and carbonic anhydrase inhibitory evaluations of benzenesulfonamide derivatives containing thiazolidinone. Molecules. 2019;24(13): 2418. doi: 10.3390\/molecules24132418.","DOI":"10.3390\/molecules24132418"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Koruza K, Murray AB, Mahon BP, Hopkins JB, Knecht W, McKenna R, et al. Biophysical characterization of cancer-related carbonic anhydrase IX. Int J Mol Sci. 2020;21(15):5277. doi: 10.3390\/ijms21155277.","DOI":"10.3390\/ijms21155277"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Lee S-H, Griffiths JR. How and why are cancers acidic? Carbonic anhydrase IX and the homeostatic control of tumour extracellular pH. Cancers (Basel). 2020 Jun 18;12(6):1616. doi: 10.3390\/cancers12061616.","DOI":"10.3390\/cancers12061616"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Strapcova S, Takacova M, Csaderova L, Martinelli P, Lukacikova L, Gal V, et al. Clinical and pre-clinical evidence of carbonic anhydrase IX in pancreatic cancer and its high expression in pre-cancerous lesions. Cancers (Basel). 2020 Jul 22;12(8):2005. doi: 10.3390\/cancers12082005","DOI":"10.3390\/cancers12082005"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Lafitte D, Lamour V, Tsvetkov PO, Makarov AA, Klich M, Pierre Deprez, et al. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5 \u2018-methyl group of the noviose. Biochemistry. 2002 Jun 11;41(23):7217-23. doi: 10.1021\/bi0159837.","DOI":"10.1021\/bi0159837"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Venugopala KN, Rashmi V, Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. Biomed Res Int. 2013;2013:963248. doi: 10.1155\/2013\/963248.","DOI":"10.1155\/2013\/963248"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Vine KL, Locke JM, Ranson M, Benkendorff K, Pyne SG, Bremner JB. In vitro cytotoxicity evaluation of some substituted isatin derivatives. Bioorg Med Chem. 2007 Jan 15;15(2):931-8. doi: 10.1016\/j.bmc.2006.10.035.","DOI":"10.1016\/j.bmc.2006.10.035"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res. 2006 Apr 15;12(8): 2622-7. doi: 10.1158\/1078-0432.CCR-05-2275.","DOI":"10.1158\/1078-0432.CCR-05-2275"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Singh A, Raghuwanshi K, Patel V, Jain D, Veerasamy R, Dixit A, et al. Assessment of 5-substituted isatin as surface recognition group: design, synthesis, and antiproliferative evaluation of hydroxamates as novel histone deacetylase inhibitors. Pharm Chem J. 2017;51(5): 366-374. doi: 10.1007\/s11094-017-1616-1","DOI":"10.1007\/s11094-017-1616-1"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Thakur A, Singla R, Jaitak V. Coumarins as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies. Eur J Med Chem. 2015 Aug 28;101:476-95. doi: 10.1016\/j.ejmech.2015.07.010.","DOI":"10.1016\/j.ejmech.2015.07.010"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Dandriyal J, Singla R, Kumar M, Jaitak V. Recent developments of C-4 substituted coumarin derivatives as anticancer agents. Eur J Med Chem. 2016 Aug 25:119:141-68. doi: 10.1016\/j.ejmech.2016.03.087.","DOI":"10.1016\/j.ejmech.2016.03.087"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Hu X-L Xu Z, Liu M-L, Feng L-S, Zhang G-D. Recent developments of coumarin hybrids as anti-fungal agents. Curr Top Med Chem. 2017; 17(29): 3219-3231. doi: 10.2174\/1568026618666171215100326.","DOI":"10.2174\/1568026618666171215100326"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Hu Y, Shen Y, Wu X, Tu X, Wang G-X Synthesis and biological evaluation of coumarin derivatives containing imidazole skeleton as potential antibacterial agents. Eur Journal Med Chem. 2018;143: 958-969. doi: 10.1016\/j.ejmech.2017.11.100.","DOI":"10.1016\/j.ejmech.2017.11.100"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Fan YL, Ke X, Liu M. Coumarin-triazole hybrids and their biological activities. J. Heterocyclic Chem. 2018;55(4):791-802. doi: 10.1002\/jhet.3112","DOI":"10.1002\/jhet.3112"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Shihan MR, Raauf AMR, Naser NH. In Silico Study and In Vitro Evaluation of Novel Synthesized Quinolone Derivatives Having Five-Membered Heterocyclic Moieties. Egypt J Chem. 2022;65(3):215-225. doi: 10.21608\/ejchem.2021.92699.4390.","DOI":"10.21608\/ejchem.2021.92699.4390"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31. Borcea A-M, Ionu\u021b I, Cri\u0219an O, Oniga O An overview of the synthesis and antimicrobial, antiprotozoal, and antitumor activity of thiazole and bisthiazole derivatives. Molecules. 2021;26(3):624. doi: 10.3390\/molecules26030624.","DOI":"10.3390\/molecules26030624"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32. Naji EM, Hussein SA, Naser NH. Evaluation of Newly Synthesized Compounds Targeting Carbonic Anhydrase Enzyme for Antineoplastic Activity in Solid Tumors. J Contemp Med Sci, 2026 Jul. 2;9(4):262-70. doi: 10.22317\/jcms.v9i4.1394.","DOI":"10.22317\/jcms.v9i4.1394"},{"key":"ref32","unstructured":"33. Abdu-Rahem LR, Ahmad AK, Abachi FT. Synthesis and medicinal attributes of thiazole derivatives: A review. Syst Rev Pharm. 2021;12(1):290-295."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34. Thomas V, Giles D, Basavarajaswamy GPM, Das AK, Patel A. Coumarin Derivatives as Anti-inflammatory and Anticancer Agents. Anticancer Agents Med Chem 2017;17(3):415-423. doi: 10.2174\/1871520616666160902094739.","DOI":"10.2174\/1871520616666160902094739"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35. Emami S, Dadashpour S. Current developments of coumarin-based anti-cancer agents in medicinal chemistry. Eur J Med Chem. 2015. 102: 611-630.","DOI":"10.1016\/j.ejmech.2015.08.033"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36. Matos J, Vazquez-Rodriguez S, Fonseca A, Uriarte, E, Santana, L Heterocyclic antioxidants in nature: coumarins. Curr Org Chem. 2017;21(4):311-324. doi: 10.2174\/1385272820666161017170652","DOI":"10.2174\/1385272820666161017170652"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37. Kurt BZ, Sonmez F, Bilen C, Ergun A, Gencer N, Arslan O, Kucukislamoglu M. Synthesis, antioxidant and carbonic anhydrase I and II inhibitory activities of novel sulphonamide-substituted coumarylthiazole derivatives. J Enzyme Inhib Med Chem. 2016 Dec;31(6):991-8. doi: 10.3109\/14756366.2015.1077823.","DOI":"10.3109\/14756366.2015.1077823"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38. Maresca A, Temperini C, Pochet L, Maseree B, Scozzafava A, Supuran CT, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010, 53, 1, 335-344. doi: 10.1021\/jm901287j","DOI":"10.1021\/jm901287j"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem. 2011 Jul; 3(9):1165-80. doi: 10.4155\/fmc.11.69.","DOI":"10.4155\/fmc.11.69"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40. Gumus A, Gumus A, Bozdag M, Akdemir A, Angeli A, Selleri S, Carta F, et al. Thiosemicarbazide-substituted coumarins as selective inhibitors of the tumor associated human carbonic anhydrases IX and XII. Molecules 2022; 27(14):4610. doi: 10.3390\/molecules27144610.","DOI":"10.3390\/molecules27144610"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:47:59Z","timestamp":1789156079000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2026i4net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202604107","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}